IN266863B - - Google Patents
Info
- Publication number
- IN266863B IN266863B IN2471KON2007A IN266863B IN 266863 B IN266863 B IN 266863B IN 2471KON2007 A IN2471KON2007 A IN 2471KON2007A IN 266863 B IN266863 B IN 266863B
- Authority
- IN
- India
- Prior art keywords
- antibodies
- disease
- integrin antibody
- integrin
- hybridoma
- Prior art date
Links
- 108010024069 integrin alpha9 Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004408 hybridoma Anatomy 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010018691 Granuloma Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005006348 | 2005-01-13 | ||
| PCT/JP2006/300676 WO2006075784A1 (ja) | 2005-01-13 | 2006-01-12 | 抗α９インテグリン抗体とその用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN266863B true IN266863B (enExample) | 2015-06-10 |
Family
ID=36677797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2471KON2007 IN266863B (enExample) | 2005-01-13 | 2006-01-12 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7595045B2 (enExample) |
| EP (1) | EP1840135B1 (enExample) |
| JP (1) | JP4871740B2 (enExample) |
| KR (1) | KR101316990B1 (enExample) |
| CN (1) | CN101103044B (enExample) |
| CA (1) | CA2593777C (enExample) |
| IN (1) | IN266863B (enExample) |
| TW (1) | TWI375565B (enExample) |
| WO (1) | WO2006075784A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2657133C (en) * | 2006-07-12 | 2017-04-11 | Gene Techno Science Co., Ltd. | Anti-human .alpha.9 integrin antibody and use of the same |
| AU2007335988A1 (en) * | 2006-12-18 | 2008-06-26 | Cartela R & D Ab | Binding agents to the integrin alpha-11 subunit, and uses thereof |
| EP2236605B1 (en) * | 2007-12-28 | 2016-06-08 | The Chemo-Sero-Therapeutic Research Institute | Human anti-alpha 9 integrin antibody |
| DK2243829T3 (da) * | 2008-01-11 | 2014-11-17 | Astellas Pharma Inc | Forbedret humaniseret anti-humant alfa-9-integrin-antistof |
| WO2009088105A1 (en) * | 2008-01-11 | 2009-07-16 | Gene Techno Science Co., Ltd. | HUMANIZED ANTI-α9 INTEGRIN ANTIBODIES AND THE USES THEREOF |
| JP5306659B2 (ja) * | 2008-01-11 | 2013-10-02 | 株式会社ジーンテクノサイエンス | 抗ヒトα９インテグリン抗体とその用途 |
| AU2009340658B2 (en) * | 2009-02-23 | 2015-02-26 | Gene Techno Science Co., Ltd. | Anti-human alpha9 integrin antibody and use thereof |
| US8735552B2 (en) | 2009-03-10 | 2014-05-27 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized K33N monoclonal antibody |
| WO2011004847A1 (ja) * | 2009-07-07 | 2011-01-13 | 一般財団法人化学及血清療法研究所 | 新規ヒト化抗ヒトα９インテグリン抗体 |
| AU2012277185A1 (en) * | 2011-06-30 | 2014-02-13 | Gene Techno Science Co., Ltd. | Soluble integrin alpha4 mutant |
| JP5687305B2 (ja) * | 2013-05-07 | 2015-03-18 | 株式会社ジーンテクノサイエンス | 抗ヒトα９インテグリン抗体とその用途 |
| CA2970058A1 (en) * | 2014-12-12 | 2016-06-16 | Commonwealth Scientific And Industrial Research Organisation | Dislodgement and release of hsc from the bone marrow stem cell niche using alpha9 integrin antagonists |
| US11806382B2 (en) | 2019-11-18 | 2023-11-07 | University Of Iowa Research Foundation | Methods of inhibiting integrin α9β1 activity |
| CN113234161B (zh) * | 2021-06-24 | 2022-06-07 | 福州迈新生物技术开发有限公司 | 抗cd3蛋白单克隆抗体及其细胞株、制备方法和应用 |
| US20250289894A1 (en) * | 2024-03-15 | 2025-09-18 | Morphic Therapeutic, Inc. | Integrin alpha-7 beta-1 antibodies and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998037914A1 (en) * | 1997-02-26 | 1998-09-03 | Toray Industries, Inc. | Remedies for hepatitis |
| AR016133A1 (es) | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
| US6939855B2 (en) * | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
| DE60229509D1 (de) | 2001-04-05 | 2008-12-04 | Astellas Pharma Inc | Anti-osteopontin-antikörper und dessen verwendung |
-
2006
- 2006-01-12 IN IN2471KON2007 patent/IN266863B/en unknown
- 2006-01-12 US US11/795,045 patent/US7595045B2/en active Active
- 2006-01-12 CN CN2006800022521A patent/CN101103044B/zh not_active Expired - Fee Related
- 2006-01-12 CA CA2593777A patent/CA2593777C/en active Active
- 2006-01-12 JP JP2006553034A patent/JP4871740B2/ja not_active Expired - Fee Related
- 2006-01-12 EP EP06700836A patent/EP1840135B1/en active Active
- 2006-01-12 KR KR1020077018346A patent/KR101316990B1/ko not_active Expired - Fee Related
- 2006-01-12 WO PCT/JP2006/300676 patent/WO2006075784A1/ja not_active Ceased
- 2006-01-13 TW TW095101325A patent/TWI375565B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200637575A (en) | 2006-11-01 |
| JPWO2006075784A1 (ja) | 2008-06-12 |
| WO2006075784A1 (ja) | 2006-07-20 |
| TWI375565B (en) | 2012-11-01 |
| EP1840135A1 (en) | 2007-10-03 |
| CA2593777C (en) | 2014-12-02 |
| US20080152653A1 (en) | 2008-06-26 |
| EP1840135A4 (en) | 2009-11-11 |
| KR20070115884A (ko) | 2007-12-06 |
| JP4871740B2 (ja) | 2012-02-08 |
| CN101103044A (zh) | 2008-01-09 |
| EP1840135B1 (en) | 2013-03-27 |
| KR101316990B1 (ko) | 2013-10-11 |
| CN101103044B (zh) | 2013-01-02 |
| US7595045B2 (en) | 2009-09-29 |
| CA2593777A1 (en) | 2006-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN266863B (enExample) | ||
| EP2388323A3 (en) | Humanized anti-9 integrin antibodies and the uses thereof | |
| NZ572756A (en) | Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody | |
| ME02499B (me) | Anti-il- 23-antitijela | |
| IL196914A (en) | Isolated monoclonal antibodies with sequences of different regions that specifically bind il-31, polynucleotide and expression vectors encoding antibodies, methods for their production and use | |
| HRP20180941T1 (hr) | Protutijela protiv il-17 | |
| IL205511A0 (en) | Methods and compositions for the production of monoclonal antibodies | |
| PH12013500912A1 (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| ZA200804346B (en) | Anit-Aß globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies | |
| NZ614857A (en) | Bispecific antibodies and methods for production thereof | |
| JP2004536568A5 (enExample) | ||
| FR2872061B1 (fr) | Composition solide divisee formee de grains a depot metallique atomique continu et son procede d'obtention | |
| PE20120815A1 (es) | Anticuerpos anti il-17f y metodos de uso de los mismos | |
| NZ591701A (en) | Use of tnf inhibitor for treatment of erosive polyarthritis | |
| NZ586357A (en) | Antibodies to the pcrv antigen of pseudomonas aeruginosa | |
| JP2011509650A5 (enExample) | ||
| ZA200508390B (en) | Compositions and methods for the therapy of inflammatory bowel disease | |
| NZ595863A (en) | Antibodies to egfl7 and methods for their use | |
| ITTO20070942A1 (it) | Composizione farmaceutica comprendente un anticorpo monoclonale anti-cd6 utile per la diagnosi e il trattamento di artrite reumatoide. | |
| IN2012DN01981A (enExample) | ||
| WO2006102200A3 (en) | Docetaxel immunoassay | |
| WO2007018853A3 (en) | Secretion of antibodies without signal peptides from bacteria | |
| NO20055420D0 (no) | Fremgangsmate for a forutsi kornstorrelsesfordeling fra formen til et sedimentaert legeme | |
| MX2008002161A (es) | Anticuerpos quimericos con regiones de primate del nuevo mundo. | |
| WO2007063415A3 (en) | Methods of producing stable b-lymphocytes |